Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Sees Significant Increase in Short Interest

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Get Free Report) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 1,190,000 shares, an increase of 14.4% from the April 15th total of 1,040,000 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 92,700 shares, the short-interest ratio is presently 12.8 days.

Institutional Trading of Aveanna Healthcare

A number of hedge funds have recently modified their holdings of the business. King Street Capital Management L.P. lifted its position in Aveanna Healthcare by 50.6% during the 4th quarter. King Street Capital Management L.P. now owns 6,400,000 shares of the company's stock valued at $17,152,000 after acquiring an additional 2,150,000 shares during the period. Nut Tree Capital Management LP lifted its holdings in shares of Aveanna Healthcare by 11.7% during the fourth quarter. Nut Tree Capital Management LP now owns 12,372,649 shares of the company's stock valued at $33,159,000 after purchasing an additional 1,296,045 shares during the last quarter. Littlejohn & Co. LLC boosted its position in shares of Aveanna Healthcare by 15.3% in the 3rd quarter. Littlejohn & Co. LLC now owns 7,446,838 shares of the company's stock worth $8,862,000 after purchasing an additional 989,260 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Aveanna Healthcare by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 2,571,251 shares of the company's stock worth $6,402,000 after buying an additional 44,970 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new position in Aveanna Healthcare during the 3rd quarter valued at approximately $36,000. Institutional investors own 87.96% of the company's stock.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft upped their target price on Aveanna Healthcare from $2.00 to $3.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Aveanna Healthcare has a consensus rating of "Hold" and an average price target of $1.80.

Aveanna Healthcare Stock Performance

Shares of NASDAQ AVAH traded up $0.09 during trading hours on Tuesday, hitting $2.57. The company's stock had a trading volume of 144,818 shares, compared to its average volume of 92,714. Aveanna Healthcare has a 12 month low of $0.85 and a 12 month high of $3.00. The stock has a market cap of $494.42 million, a price-to-earnings ratio of -4.25 and a beta of 2.02. The business has a 50-day simple moving average of $2.38 and a 200-day simple moving average of $2.34.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The business had revenue of $490.65 million during the quarter, compared to the consensus estimate of $485.05 million. During the same quarter in the prior year, the business posted ($0.06) earnings per share. On average, equities research analysts forecast that Aveanna Healthcare will post -0.14 EPS for the current year.

About Aveanna Healthcare

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.